What is the Chinese name of Imdelltra

Talatuzumab is a bispecific antibody drug developed by the American company Amgen. It has been approved in the United States for the treatment of specific types of small cell lung cancer. The price is relatively high, about US$6,102 for 1 mg and US$28,129 for 10 mg.

What is the Chinese name of Imdelltra?

The Chinese generic name of Imdelltra is "tarlatumab", and other nicknames include tarlatamab-dlle and AMG757. The basic information and scope of application of this drug will be introduced in detail below.

What is Imdelltra?

Talatumumab is a bispecific antibody drug targeting DLL3/CD3, which recognizes and eliminates tumor cells expressing DLL3 by activating T cells. Its mechanism of action is to guide T cells to the tumor site and release cytotoxic substances. It is suitable for lung cancer patients in whom traditional chemotherapy is ineffective. The pharmaceutical dosage form is freeze-dried powder injection, which requires intravenous infusion.

Indications for Imdelltra

Talatuzumab is indicated for the treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed after receiving platinum-containing chemotherapy. This indication is based on the accelerated approval process and requires further clinical trials to verify long-term efficacy. Patients must have a doctor evaluate their tumor type and treatment history before use, and strictly follow the medication indications.

Talatuzumab is contraindicated in pregnant women, lactating women, children and those allergic to drug ingredients. Patients with severe hepatic and renal insufficiency need to be carefully evaluated, and no dose adjustment is required in the elderly, but clinical data are limited.

Usage and dosage of Imdelltra

Talatuzumab needs to be administered by medical staff in professional medical institutions to reduce treatment risks.

Preparation before administration

Before administration, patients need to check blood routine, liver and kidney function and infection indicators. Dexamethasone (8 mg) should be administered intravenously 1 hour before the first infusion to prevent cytokine release syndrome (CRS). During the infusion period, patients need to be hospitalized and monitored for 24 hours. Patients must be accompanied by family members within 48 hours of taking the medicine and live near a medical institution.

Recommended dose and treatment course

Adopt a dose escalation plan: use 1mg on the 1st day of cycle 1, increase to 10mg on the 8th day, and maintain the 10mg dose every two weeks thereafter. The infusion time needs to be controlled within 1 hour, and an infusion device made of EVA or polyolefin should be used. If medication is suspended due to adverse reactions, the patient needs to readjust the dose according to the interval, and the specific rules must be followed by the doctor's advice.

When reconstituting the drug, add 1.3 mL of sterile water for injection for the 1 mg specification and 4.4 mL for the 10 mg specification. Shake gently to dissolve and dilute immediately. Talatumumab diluent should be used within 4 hours and avoid repeated refrigeration.

What side effects will Imdelltra cause?

Talatuzumab may cause a variety of adverse reactions, which require close monitoring and timely treatment.

Common side effects and treatments

Cytokine release syndrome manifests as fever, hypotension, or difficulty breathing. For grade 1 CRS, the medication can be suspended and antipyretic drugs can be given; for grade 2 and above, hospitalization is required and tocilizumab or hormone therapy is used. Fatigue, dysgeusia, etc. can be relieved by adjusting diet and rest. In severe cases, treatment needs to be suspended.

Serious side effects and first aid measures

Symptoms of neurotoxicity include confusion, disorientation, or seizures. If such symptoms occur, the drug should be discontinued immediately, a neurological evaluation should be performed, and dexamethasone should be used as directed by your doctor. Grade 4 neurotoxicity or recurrent grade 3 reactions require permanent discontinuation. In case of neutropenia or infection, the medication needs to be suspended and white blood injection or antibiotic treatment should be given.

Lung cancer patients need to maintain a balanced diet and supplement protein and vitamins in an appropriate amount. Avoid smoking and exposure to second-hand smoke, and engage in regular light exercise to enhance your physical fitness.